A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics

Salvia divinorum is a perennial shrub traditionally used by the Mazatec people of Oaxaca for ritual and medicinal purposes. Cruz and colleagues explain that the principal bioactive constituent of the plant is salvinorin A, a non‑nitrogenous neoclerodane diterpene that produces intense, short‑lived hallucinations and is a highly selective kappa‑opioid receptor (KOR) agonist. Clerodane diterpenes in general have attracted interest because of diverse biological activities, and salvinorin A stands out because its structure and receptor interactions differ from classical alkaloid opioids and serotonergic psychedelics. This paper reviews the pharmacology, pharmacokinetics, behavioural effects and potential therapeutic roles of salvinorin A, and highlights unresolved questions about its mechanism, metabolism, toxicity and long‑term effects. The authors aim to synthesise preclinical and observational evidence on antinociceptive, antidepressant, anti‑addiction, neuroprotective, anti‑inflammatory and gastrointestinal activities, and to discuss potential applications and safety concerns for human therapeutics.

Chemical and receptor pharmacology: The review emphasises that salvinorin A is the major bioactive compound of S. divinorum and is a potent, highly selective KOR agonist. Unlike classical opioid ligands, it lacks a basic nitrogen atom, representing a structurally novel class of opioid ligands. The extracted text gives the molecular formula as C23H28O8 and a molar mass of about 432 g mol−1. In silico receptorome work cited in the review suggests other diterpenes in the plant are present at lower concentrations and are unlikely to account for the plant’s psychoactivity. Pharmacokinetics and metabolism: Pharmacokinetic findings reported include very rapid brain uptake in primate PET imaging, with the highest brain concentrations observed in cerebellum. Metabolism appears to include rapid ester hydrolysis of the 2‑acetoxy group to form salvinorin B and involvement of multiple CYP450 isoforms (CYP2D6, CYP2C18, CYP1A1 and CYP2E1) as well as glucuronosyltransferases. Salvinorin A was reported as a substrate for P‑glycoprotein in vitro, but its lipophilicity and permeability may reduce functional efflux from the CNS. Two half‑life estimates appear in the extracted text: 75 minutes (with reported clearance of 26 L/h/kg) and an earlier report of about 56 minutes in rhesus monkeys; the text does not clearly reconcile these values. The authors state that smoking produces pronounced effects and that the compound is absorbed through oral mucosa to a smaller degree; the extraction reports that “smoking only 200–500 mg” induces short‑lasting (up to 1 hour) intense hallucinations, but it is not clear from the extracted text whether that amount refers to plant material or to isolated compound. Effects on monoamines and behaviour: Multiple studies in rodents show that salvinorin A reduces dopamine levels in striatal regions (caudate putamen and nucleus accumbens), and alters serotonin and noradrenaline release in various synaptosomal preparations. Behaviourally, these neurochemical effects are associated with decreased locomotor activity, sedation and anhedonia in some paradigms. The compound also inhibited cocaine‑induced drug‑seeking in animal models, and attenuated cocaine‑induced behaviours, consistent with other KOR agonists' modulation of the mesolimbic dopamine system. Drug addiction and human use data: The authors review evidence that low doses in rodents (reported ranges 0.1–40 mg/kg) produced rewarding effects in place preference and self‑administration tests, whereas a high dose (160 mg/kg cited) produced aversive responses. The review also notes metabolic pathway overlap between salvinorin A and several abused drugs (for example, glucuronosyltransferase and various CYP enzymes), which could produce drug–drug interactions. A survey of 500 regular S. divinorum users is reported in which 0.6% self‑identified as feeling addicted or dependent; the review states there are no case reports demonstrating addiction to S. divinorum. Antinociceptive and analgesic effects: Preclinical analgesic effects were observed in tail‑flick, hot‑plate and abdominal constriction tests in mice, and in a mustard oil visceral pain model; these effects were dose‑dependent and short‑lived (around 20 minutes). The antinociception was not altered by mu or delta opioid antagonists, supporting a KOR‑mediated mechanism. The review contrasts the short duration of salvinorin A analgesia with longer‑acting mu opioid painkillers, and highlights the absence of reported dependence in animal studies as a potential advantage. Neurological and psychiatric effects: Animal behavioural studies and limited human case material are summarised. A single human case is cited in which a 26‑year‑old woman reported remission of chronic depression after minimal, regular oral use of S. divinorum; the review also cites forced‑swim test data in rats where a wide dose range (0.001–1000 mg/kg) produced antidepressant‑like effects reversible by a selective KOR antagonist. Conversely, higher doses (for example 2.0 mg/kg in one rat study) produced depressive‑like behaviour, reduced locomotion and impaired motivation, indicating dose‑dependent bidirectional effects. Anxiolytic effects were reported at low doses in rodents, whereas high doses produced cognitive deficits resembling ketamine‑like effects. The compound showed neuroprotective properties in cerebral ischaemia models, modulating aquaporin‑4 expression and reducing brain oedema and neuronal injury in hippocampus, cortex and striatum in preclinical work. Gastrointestinal and anti‑inflammatory actions: Preclinical work demonstrated inhibition of gastrointestinal motility in mice and suppression of myenteric cholinergic transmission in guinea‑pig ileum mediated by KOR activation, suggesting a pharmacological basis for traditional uses in diarrhoea. In two mouse colitis models, salvinorin A produced anti‑inflammatory effects mediated by KOR and cannabinoid receptor 1 (CB1), and reduced intestinal pain. The review also reports that salvinorin A inhibited leukotriene production in activated macrophages, implicating modulation of inflammatory lipid mediator biosynthesis. Toxicity and safety data: Short‑term toxicity studies in rats (2‑week exposure at various concentrations) reportedly showed no histological changes in spleen, brain, liver, kidney, blood and bone marrow. However, an in vitro study across six cell lines (N27, Caco‑2, HepG2, COS‑7 and HEK‑293 among them) found dose‑ and time‑dependent cytotoxicity, prompting the authors to call for more studies on chronic and continuous consumption. The review also notes that the intense hallucinations, dissociation, dysphoria and motor effects are major concerns for therapeutic use. Overall, the extracted text emphasises that human therapeutic trials are lacking and the long‑term safety profile remains unclear.

Cruz and colleagues interpret the collected literature as indicating that salvinorin A defines a novel, non‑nitrogenous class of selective KOR agonists with a broad preclinical pharmacological profile. They posit potential therapeutic applications across pain, addiction, neuroprotection, inflammatory disorders and gastrointestinal conditions, and note that semi‑synthetic analogues based on salvinorin A’s chemical scaffold are being developed to explore mixed opioid/cannabinoid activity and to refine pharmacokinetic and safety properties. The authors caution that several important uncertainties temper enthusiasm for clinical use. Key gaps include incomplete characterisation of mechanism(s) of action in humans, variable and partly inconsistent pharmacokinetic estimates reported in preclinical studies, possible drug–drug interactions owing to shared metabolic pathways with other drugs of abuse, and limited toxicity data—particularly for chronic exposure. They also highlight the compound’s intense psychotomimetic effects, arguing these would be undesirable in a therapeutic agent and present a safety concern for non‑controlled use. Implications discussed include the need for more preclinical work to elucidate receptor interactions and downstream signalling, development of analogues that retain therapeutic effects while minimising hallucinatory side‑effects, and properly controlled human studies to assess efficacy and safety. The authors stress that the recreational availability and low cost of S. divinorum have produced widespread non‑medical use, which complicates assessment of benefit–risk and underscores the importance of further research and regulatory consideration.

In their concluding remarks the authors restate that salvinorin A is the principal psychoactive component of S. divinorum and represents a unique class of selective KOR agonists with multiple preclinical therapeutic properties. They emphasise that, despite promising effects in animal models—antinociceptive, antidepressant, anti‑addiction, neuroprotective and anti‑inflammatory—there are no controlled studies demonstrating therapeutic benefit in humans. The review closes by calling for further research into pharmacology, long‑term safety and strategies to dissociate therapeutic actions from intense hallucinatory side‑effects, while acknowledging both the therapeutic potential of salvinorin A and the public‑health concerns arising from its recreational use.